ArticleThe Journal of experimental medicine1999
A kinetic threshold between negative and positive selection based on the longevity of the T cell receptor-ligand complex.
Article in The Journal of experimental medicine, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 119 citations in OpenAlex.
- Modulation of antigen discrimination by duration of immune contacts in a kinetic proofreading model of T cell activation with extreme statistics.PLoS computational biology · 2023Article
- Characterizing T cell responses to enzymatically modified beta cell neo-epitopes.Frontiers in immunology · 2022Article
- Hybrid Insulin Peptides Are Recognized by Human T Cells in the Context of DRB1*04:01.Diabetes · 2020Article
- A cell topography-based mechanism for ligand discrimination by the T cell receptor.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Modifying Enzymes Are Elicited by ER Stress, Generating Epitopes That Are Selectively Recognized by CD4Diabetes · 2018Article
- Early T cell receptor signals globally modulate ligand:receptor affinities during antigen discrimination.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- TGF-β1 along with other platelet contents augments Treg cells to suppress anti-FVIII immune responses in hemophilia A mice.Blood advances · 2016Article
- Article
- TCR affinity and tolerance mechanisms converge to shape T cell diabetogenic potential.Journal of immunology (Baltimore, Md. : 1950) · 2014Article
- To affinity and beyond: harnessing the T cell receptor for cancer immunotherapy.Human vaccines & immunotherapeutics · 2014Review
- Chronic follicular bronchiolitis requires antigen-specific regulatory T cell control to prevent fatal disease progression.Journal of immunology (Baltimore, Md. : 1950) · 2013Article
- Direct single molecule measurement of TCR triggering by agonist pMHC in living primary T cells.eLife · 2013Article
- Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity.Cancer cell · 2013Article
- Subtle changes in TCRα CDR1 profoundly increase the sensitivity of CD4 T cells.Molecular immunology · 2013Article
- Models of self-peptide sampling by developing T cells identify candidate mechanisms of thymic selection.PLoS computational biology · 2013Article
- T-cell receptor retrogenic mice: a rapid, flexible alternative to T-cell receptor transgenic mice.Immunology · 2012Review
- T-cell receptor affinity in thymic development.Immunology · 2012Review
- Long-term persistence of CD4(+) but rapid disappearance of CD8(+) T cells expressing an MHC class I-restricted TCR of nanomolar affinity.Molecular therapy : the journal of the American Society of Gene Therapy · 2012Article
- How the TCR balances sensitivity and specificity for the recognition of self and pathogens.Nature immunology · 2012Review
- Structure of a TCR with high affinity for self-antigen reveals basis for escape from negative selection.The EMBO journal · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
We have developed a unique in vivo system to determine the relationship between endogenous altered peptide ligands and the development of major histocompatibility complex class II- restricted T cells. Our studies use the 3.L2 T cell receptor (TCR) transgenic mouse, in which T cells are specific for Hb(64-76)/I-Ek and positively selected on I-Ek plus self-peptides. To this endogenous peptide repertoire, we have individually added one of six well-characterized 3.L2 ligands. This transgenic approach expands rather than constrains the repertoire of self-peptides. We find that a broad range of ligands produce negative selection of thymocytes in vivo. When compared with the in vitro TCR-ligand binding kinetics, we find that these negatively selecting ligands all have a half-life of 2 s or greater. Additionally, one of two ligands examined with no detectable binding to the 3.L2 TCR and no activity on mature 3.L2 T cells (Q72) enhances the positive selection of transgenic thymocytes in vivo. Together, these data establish a kinetic threshold between negative and positive selection based on the longevity of TCR-ligand complexes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.